Rituximab monoclonal antibody as initial systemic therapy for patients with low-grade non-Hodgkin lymphoma

Blood

Volumn 95, Issue 10, 2000, Pages 3052-3056

  Hainsworth, John D ^a   Burris III, Howard A ^b   Morrissey, Lisa H ^b   Litchy, Sharlene ^b   Scullin Jr , Daniel C ^b   Bearden III, James D ^b   Richards, Paul ^b   Greco, F Anthony ^b  

^a SARAH CANNON RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

RITUXIMAB;

ADULT; AGED; ARTICLE; CANCER GRADING; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; DISEASE SEVERITY; DRUG EFFICACY; FATIGUE; FEMALE; FEVER; FLUSHING; FOLLOW UP; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOTENSION; MALE; NAUSEA; NONHODGKIN LYMPHOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

EID: 0034657295     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v95.10.3052.010k30_3052_3056     Document Type: Article

References (9)

1. Ezdinli EZ, Anderson JR, Melvin F, et al. Moderate versus aggressive chemotherapy of nodular lymphocytic poorly differentiated lymphoma. J Clin Oncol. 1985;3:769-775.
2. Dana BW, Dahlberg S, Nathwani BN, et al. Long-term follow-up of patients with low-grade malignant lymphomas treated with doxorubicin-based chemotherapy or chemoimmunotherapy. J Clin Oncol. 1993;11:644-659.
3. Miller RA, Maloney DG, Warnke R, Levy R. Treatment of B-cell lymphoma with monoclonal anti-idiotype antibody. N Engl J Med. 1982;306:517-520.
4. Maloney DG, Grillo-Lopez AJ, White CA, et al. IDEC-C2B8 (rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood. 1997;90: 2188-2195.
5. McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol. 1998;16:2825-2833.
6. Davis T, Levy R, White CA, et al. Retreatment with Rituxan (rituximab, Idec C2B8) have significant efficacy, do not cause hama, and are a viable minimally toxic alternative in relapsed or refractory non-Hodgkin's lymphoma [abstract 1710]. Blood. 1998;91:509A.
7. Coiffier B, Haioun C, Ketterer N, et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study. Blood 1998;92:1927-1932.
8. Solal-Celigny P, Brousse N, Eftekhari P, et al. Rituximab as first-line treatment of follicular lymphoma patients with a low tumor burden. Preliminary results of a phase II trial [abstract]. Ann Oncol. 1999;10(suppl 3):130.
9. Czuczman MS, Grillo-Lopez AJ, White CA, et al. Treatment of patients with low-grade B-cell lymphoma with the combination of chimeric anti-CD20 monoclonal antibody and CHOP chemotherapy. J Clin Oncol. 1999;17:268-276.